Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 2
2015 2
2016 3
2017 2
2018 1
2019 1
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Asienzo J, Kaimal A, Mirembe G, Lugemwa A, Ategeka G, Borok M, Mugerwa H, Siika A, Odongpiny ELA, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. Paton NI, et al. Lancet HIV. 2022 Jun;9(6):e381-e393. doi: 10.1016/S2352-3018(22)00092-3. Epub 2022 Apr 20. Lancet HIV. 2022. PMID: 35460601 Free article. Clinical Trial.
Point-prevalence survey of antibiotic use at three public referral hospitals in Kenya.
Omulo S, Oluka M, Achieng L, Osoro E, Kinuthia R, Guantai A, Opanga SA, Ongayo M, Ndegwa L, Verani JR, Wesangula E, Nyakiba J, Makori J, Sugut W, Kwobah C, Osuka H, Njenga MK, Call DR, Palmer GH, VanderEnde D, Luvsansharav UO. Omulo S, et al. Among authors: kwobah c. PLoS One. 2022 Jun 16;17(6):e0270048. doi: 10.1371/journal.pone.0270048. eCollection 2022. PLoS One. 2022. PMID: 35709220 Free PMC article.
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Kaimal A, Mirembe G, Tukamushabe P, Ategeka G, Hakim J, Mugerwa H, Siika A, Asienzo J, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. Paton NI, et al. N Engl J Med. 2021 Jul 22;385(4):330-341. doi: 10.1056/NEJMoa2101609. N Engl J Med. 2021. PMID: 34289276 Clinical Trial.
Opportunities for Improving Antimicrobial Stewardship: Findings From a Prospective, Multi-Center Study in Three Low- or Middle-Income Countries.
Muro FJ, Lyamuya FS, Kwobah C, Bollinger J, Bodinayake CK, Nagahawatte A, Piyasiri B, Kurukulasooriya R, Ali S, Mallya R, Rolfe R Jr, Ruwanpathirana A, Sheng T, Østbye T, Drew R, Kussin P, Woods CW, Anderson DJ, Mmbaga BT, Tillekeratne LG. Muro FJ, et al. Among authors: kwobah c. Front Public Health. 2022 Apr 25;10:848802. doi: 10.3389/fpubh.2022.848802. eCollection 2022. Front Public Health. 2022. PMID: 35548085 Free PMC article.
Barriers to implementing antimicrobial stewardship programs in three low- and middle-income country tertiary care settings: findings from a multi-site qualitative study.
Rolfe R Jr, Kwobah C, Muro F, Ruwanpathirana A, Lyamuya F, Bodinayake C, Nagahawatte A, Piyasiri B, Sheng T, Bollinger J, Zhang C, Ostbye T, Ali S, Drew R, Kussin P, Anderson DJ, Woods CW, Watt MH, Mmbaga BT, Tillekeratne LG. Rolfe R Jr, et al. Among authors: kwobah c. Antimicrob Resist Infect Control. 2021 Mar 25;10(1):60. doi: 10.1186/s13756-021-00929-4. Antimicrob Resist Infect Control. 2021. PMID: 33766135 Free PMC article.
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, van Oosterhout JJ, Kiconco M, Siika A, Mwebaze R, Abwola M, Abongomera G, Mweemba A, Alima H, Atwongyeire D, Nyirenda R, Boles J, Thompson J, Tumukunde D, Chidziva E, Mambule I, Arribas JR, Easterbrook PJ, Hakim J, Walker AS, Mugyenyi P; EARNEST Trial Team. Paton NI, et al. N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274. N Engl J Med. 2014. PMID: 25014688 Free article. Clinical Trial.
Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses From the EARNEST Trial.
Kambugu A, Thompson J, Hakim J, Tumukunde D, van Oosterhout JJ, Mwebaze R, Hoppe A, Abach J, Kwobah C, Arenas-Pinto A, Walker SA, Paton NI; EARNEST Trial Team. Kambugu A, et al. Among authors: kwobah c. J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):506-13. doi: 10.1097/QAI.0000000000000898. J Acquir Immune Defic Syndr. 2016. PMID: 26579985 Clinical Trial.
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Paton NI, et al. Lancet HIV. 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub 2017 May 8. Lancet HIV. 2017. PMID: 28495562 Free PMC article. Clinical Trial.
15 results